De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!

Mayne Pharma Group Balans Gezondheid

Financiële gezondheid criteriumcontroles 5/6

Mayne Pharma Group heeft een totaal eigen vermogen van A$454.2M en een totale schuld van A$31.6M, wat de schuld-eigenvermogensverhouding op 7% brengt. De totale activa en totale passiva bedragen respectievelijk A$1.1B en A$689.0M.

Belangrijke informatie

7.0%

Verhouding schuld/eigen vermogen

AU$31.64m

Schuld

Rente dekkingsratio	n/a
Contant	AU$149.28m
Aandelen	AU$454.19m
Totaal verplichtingen	AU$688.99m
Totaal activa	AU$1.14b

Recente financiële gezondheidsupdates

Geen updates

Recent updates

Analyse van de financiële positie

Kortlopende schulden: De korte termijn activa ( A$460.6M ) HG6 } overtreffen de korte termijn passiva ( A$313.9M ).

Langlopende schulden: De kortetermijnactiva HG6 ( A$460.6M ) overtreffen de langetermijnschulden ( A$375.1M ).

Schuld/ eigen vermogen geschiedenis en analyse

Schuldniveau: HG6 heeft meer geld in kas dan de totale schuld.

Schuld verminderen: De schuld/eigen vermogen-ratio van HG6 is de afgelopen 5 jaar gedaald van 36.5% naar 7%.

Balans

Analyse van de cashflow

Voor bedrijven die in het verleden gemiddeld verliesgevend zijn geweest, beoordelen we of ze ten minste 1 jaar kasstroom hebben.

Stabiele cash runway: HG6 heeft op basis van de huidige vrije kasstroom voldoende cash runway voor meer dan 3 jaar.

Voorspelling contante baan: HG6 heeft minder dan een jaar aan kasmiddelen als de vrije kasstroom blijft dalen met historische percentages van 49.3 % per jaar.

Mayne Pharma Group Balans Gezondheid

Financiële gezondheid criteriumcontroles 5/6

Belangrijke informatie

Recente financiële gezondheidsupdates

Recent updates

Full year 2024 earnings released: AU$2.12 loss per share (vs AU$3.86 loss in FY 2023)

No longer forecast to breakeven

New minor risk - Profitability

First half 2024 earnings released: AU$0.88 loss per share (vs AU$1.38 loss in 1H 2023)

Forecast to breakeven in 2026

New minor risk - Share price stability

Mayne Pharma Group Limited to Report Fiscal Year 2024 Results on Aug 23, 2024

Mayne Pharma Group Limited to Report First Half, 2024 Results on Feb 26, 2024

High number of new directors

Mayne Pharma Group Limited Approves Election of Anne Lockwood

CEO, MD & Director recently bought €84k worth of stock

Mayne Pharma Group Limited, Annual General Meeting, Nov 30, 2023

Full year 2023 earnings released: AU$3.86 loss per share (vs AU$3.20 loss in FY 2022)

New minor risk - Financial data availability

Mayne Pharma Group Limited to Report Fiscal Year 2023 Results on Aug 31, 2023

Mayne Pharma Group Limited Announces Retirement of Carolyn Myers from the Board At the End of July 2023

First half 2023 earnings released: AU$0.078 loss per share (vs AU$0.62 loss in 1H 2022)

Mayne Pharma Group Limited to Report First Half, 2023 Results on Feb 28, 2023

Mayne Pharma Group Limited and Mithra Pharmaceuticals, SA Announces US Launch of Haloette, a Generic Version of Nuvaring

Inaugural dividend of AU$0.065 per share

Now 48% undervalued after recent price drop

Mayne Pharma Group Limited (ASX:MYX) agreed to acquire Certain Assets of TherapeuticsMD, Inc. (NasdaqGS:TXMD).

High number of new directors

High number of new directors

Mayne Pharma Group Limited Declares Fully Franked Special Dividend, Payable on 27 January 2023

Catalent, Inc. (NYSE:CTLT) acquired Metrics, Inc. from Mayne Pharma Group Limited (ASX:MYX) for approximately $480 million.

Mayne Pharma Group Limited Announces Executive Changes Effective from 1 October 2022

Mayne Pharma Group Limited Announces Management Changes

Full year 2022 earnings released: AU$0.16 loss per share (vs AU$0.13 loss in FY 2021)

Scott Richards Plans to Retire as CEO of Mayne Pharma Group Limited

FDA Grants Approval to Mayne Pharma Group Limited and Mithra Pharmaceuticals, SA of the Abbreviated New Drug Application (Anda) for Haloette

Mayne Pharma Group Limited and Mithra Pharmaceuticals, Sa Announces NEXTSTELLIS Oral Contraceptive Now Available in Australia

Mayne Pharma Group Limited Announces CFO Changes

Forecast breakeven date pushed back to 2024

First half 2022 earnings: EPS in line with expectations, revenues disappoint

Mayne Pharma Expands U.S Dermatology Portfolio

Insufficient new directors

Mayne Pharma Group Limited and Mithra Pharmaceuticals, SA Announces Therapeutic Goods Administration Approval of NEXTSTELLIS® Oral Contraceptive

High number of new directors

Independent Non Executive Director Bruce Mathieson has left the company

Independent Chairman Roger Corbett has left the company

Independent Chairman Roger Corbett has left the company

U.S. Food and Drug Administration Approves Mayne Pharma LEXETTE for Adolescent Plaque Psoriasis

Forecast to breakeven in 2023

Independent Non-Executive Director recently bought €85k worth of stock

Full year 2021 earnings released: AU$0.13 loss per share (vs AU$0.061 loss in FY 2020)

Mayne Pharma Group Limited and Mithra Pharmaceuticals, SA Announces Nextstellis Receives FDA Marketing Exclusivity and Phase Iii Data Published

Mayne Pharma Announces New Data Showing Treatment with Nextstellis® Investigational Combined Oral Contraceptive (Coc) Containing Drospirenone (Drsp) and Estetrol

Mayne Pharma Group Limited Launches Another Generic Oral Contraceptive

First half 2021 earnings released: AU$0.12 loss per share (vs AU$0.012 loss in 1H 2020)

Revenue beats expectations

Mayne Pharma Group Limited to Report Fiscal Year 2021 Results on Aug 27, 2021

Mayne Pharma Group Limited Launches MICROGESTIN 24 FE Tablets in the United States

New 90-day high: €0.24

Mayne Pharma Group Limited Provides Update on Women's Health Pipeline

Mayne Pharma Group Limited Appoints Peter Paltoglou as Chief Financial Officer

Full year earnings released

Mayne Pharma Group Limited to Report Fiscal Year 2020 Results on Aug 21, 2020

Mayne Pharma Group Limited(ASX:MYX) dropped from S&P/ASX 200 Index

Analyse van de financiële positie

Schuld/ eigen vermogen geschiedenis en analyse

Balans

Analyse van de cashflow

Ontdek gezonde bedrijven